ABL Bio Inc - Asset Resilience Ratio

Latest as of June 2026: 0.77%

ABL Bio Inc (298380) has an Asset Resilience Ratio of 0.77% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ABL Bio Inc (298380) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩2.10 Billion

≈ $1.42 Million USD Cash + Short-term Investments

Total Assets

₩273.72 Billion

≈ $185.50 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how ABL Bio Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ABL Bio Inc total assets.

Liquid Assets Composition Over Time

This chart breaks down ABL Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of ABL Bio Inc to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩2.10 Billion	0.77%
Total Liquid Assets	₩2.10 Billion	0.77%

Asset Resilience Insights

Limited Liquidity: ABL Bio Inc maintains only 0.77% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ABL Bio Inc Industry Peers by Asset Resilience Ratio

Compare ABL Bio Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Aktis Oncology, Inc. Common stock NASDAQ:AKTS	Biotechnology	23.64%
Neurotech International Ltd AU:NTI	Biotechnology	0.22%
Jazz Pharmaceuticals plc F:J7Z	Biotechnology	8.68%
GT Biopharma Inc NASDAQ:GTBP	Biotechnology	0.00%
Herantis Pharma Oyj HE:HRTIS	Biotechnology	89.18%
Sinocelltech Group Ltd SHG:688520	Biotechnology	5.27%
Sprint Bioscience AB ST:SPRINT	Biotechnology	77.81%
Synlogic Inc NASDAQ:SYBX	Biotechnology	0.00%

Annual Asset Resilience Ratio for ABL Bio Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for ABL Bio Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.05%	₩2.96 Billion ≈ $2.01 Million	₩280.93 Billion ≈ $190.39 Million	-59.58pp
2024-12-31	60.64%	₩140.66 Billion ≈ $95.32 Million	₩231.98 Billion ≈ $157.21 Million	+16.21pp
2023-12-31	44.43%	₩71.15 Billion ≈ $48.22 Million	₩160.14 Billion ≈ $108.53 Million	+2.14pp
2022-12-31	42.29%	₩78.32 Billion ≈ $53.07 Million	₩185.18 Billion ≈ $125.49 Million	-24.39pp
2021-12-31	66.68%	₩43.65 Billion ≈ $29.58 Million	₩65.45 Billion ≈ $44.36 Million	-3.78pp
2020-12-31	70.47%	₩70.39 Billion ≈ $47.70 Million	₩99.89 Billion ≈ $67.70 Million	-22.81pp
2019-12-31	93.27%	₩133.29 Billion ≈ $90.33 Million	₩142.90 Billion ≈ $96.84 Million	+10.41pp
2018-12-31	82.86%	₩139.92 Billion ≈ $94.82 Million	₩168.87 Billion ≈ $114.44 Million	+37.84pp
2017-12-31	45.02%	₩9.17 Billion ≈ $6.21 Million	₩20.37 Billion ≈ $13.80 Million	-25.89pp
2016-12-31	70.91%	₩5.34 Billion ≈ $3.62 Million	₩7.53 Billion ≈ $5.10 Million	--

pp = percentage points

About ABL Bio Inc

KQ:298380 Korea Biotechnology

Market Cap

$1.94 Billion

₩2.86 Trillion KRW

Market Cap Rank

#6346 Global

#152 in Korea

Share Price

₩51100.00

Change (1 day)

-5.19%

52-Week Range

₩51100.00 - ₩245500.00

All Time High

₩245500.00